[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anorexia-nervosa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anorexia-nervosa":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,95,0,25,[9,54,76,99,127,150,181,208,236,260,285,304,329,352,378,412,432,448,474,493,511,538,559,581,608],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100639845","eating-disorder-dynamic-intervention-100639845",false,"NCT07600671","Eating Disorder Dynamic Intervention","Rapid Innovation of Precision Psychiatry Interventions Using Dynamic Systems Modeling and Ecological Quasi-Experiments","EDDI","Inclusion Criteria:\n\n1. Age 18-70\n2. At least 12 ED behaviors from the same behavioral category in the past 12 weeks (i.e., at least 12 binge eating episodes, at least 12 compensatory behaviors, and\u002For at least 12 instances of dietary restriction)\n3. Ownership of a smartphone\n4. Willingness to complete ecological momentary assessment (EMA) and sensor data collection\n5. Live in the United States\n6. Has a primary care provider or is willing to establish a primary care provider\n\nExclusion Criteria:\n\n1. Inability to fluently speak, read, and write in English\n2. Body mass index \\\u003C 17.5 kg\u002Fm2\n3. Medical complications of ED symptoms requiring immediate treatment\n4. Current ED-focused therapy\n5. Severe psychopathology (i.e., active suicidal ideation, psychosis, bipolar disorder, or substance use disorder) or intellectual disability inhibiting engagement in study protocols","ALL","18 Years","70 Years",{"count":22,"type":23},170,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this study is to develop and test a digital program to help people with eating disorders in their everyday lives. The program uses brief surveys and sensor data collected by smartphones to understand when someone may be at higher risk for behaviors like restricting food, binge eating, or using unhealthy weight control behaviors.",[29,30,31,32,33],"Eating Disorders","Anorexia Nervosa","Bulimia Nervosa","Binge Eating Disorder","Other Specified Feeding or Eating Disorder",[35,36,37,38,39,40,41],"binge eating","eating problem","eating disorder","purging","restriction","weight control behavior","dieting","RECRUITING","2026-06-29",{"date":45,"type":46},"2026-07-01","ACTUAL",{"date":43,"type":46},{"date":49,"type":23},"2030-07-31",{"name":51,"class":52},"Trustees of Dartmouth College","OTHER",1,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":19,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":53},"100497945","interoceptive-exposure-for-adolescents-with-low-weight-eating-disorders-100497945","NCT05763849","Interoceptive Exposure for Adolescents With Low Weight Eating Disorders","A Confirmatory Efficacy Study of Interoceptive Exposure for Adolescents With Low Weight Eating Disorders","Inclusion Criteria:\n\n* Aged 12-18\n* Speak English\n* Permission from pediatrician or equivalent to receive outpatient care\n* Clinically significant restriction of food intake by EDA-5 or evidence of persistent food avoidance from patient or guardians\n* Evidence of the inability to maintain greater than minimally low body weight based on BMI for age percentiles and growth trajectories\n\nExclusion Criteria:\n\n* Comorbid psychotic or bipolar disorder\n* Active suicidal ideation\n* Current substance dependence\n* Psychiatric medication initiated or dosage changes \\\u003C2 weeks from baseline\n* Major medical illness (e.g., diabetes mellitus, Crohn's disease, etc.)","12 Years",{"count":63,"type":23},120,[26],"This project includes a parallel group randomized controlled trial comparing two psychological treatments: 1) Exposure-based Family Therapy (IE) vs. 2) Family Based Therapy (FBT) for low weight eating disorders with 12 month follow-up. Primary outcomes are expected body weight and clinical impairment. Three mechanisms of change (Autonomous Eating, Non-Judgmental Body Awareness, and Extinction Learning) will be examined in a process mediation models of change.",[30],"2026-06-17",{"date":69,"type":46},"2026-06-22",{"date":71,"type":46},"2023-03-14",{"date":73,"type":23},"2028-01",{"name":75,"class":52},"Icahn School of Medicine at Mount Sinai",{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100619907","inpatient-care-of-patients-with-difficult-to-treat-anorexia-nervosa---factors-affecting-treatment-outcome-100619907","NCT07350720","Inpatient Care of Patients With Difficult to Treat Anorexia Nervosa - Factors Affecting Treatment Outcome.","Inpatient Care of Patients With Difficult to Treat Eating Disorders - What Affects Treatment Outcome?","Inclusion Criteria:\n\n* Anorexia Nervosa diagnosis (ICD F50.0)\n* Admitted to inpatient care at department 5 at Region Skåne Eating Disorders Center\n\nExclusion Criteria:\n\n* Confidential identity\n* Inability to read or write in Swedish or English\n* Condition or treatment that, according to the study team, makes participation in the study inappropriate","64 Years",{"count":85,"type":23},100,"OBSERVATIONAL","The overall aim of the project is to investigate factors that may influence treatment outcomes in people with difficult-to-treat anorexia nervosa who are enrolled in inpatient care at the Region Skåne Eating Disorders Centre in Lund. Treatment expectations, sense of autonomy, and patient participation, will be investigated, as well as caregivers' attitudes towards, and experiences of working with, autonomy and patient participation in the inpatient setting. The research project is expected to contribute to increased knowledge about the treatment of difficult-to-treat anorexia nervosa, and what part patient participation and autonomy may play when treating severe eating disorders. The overall objectives of the research program are:\n\n1. To contribute to increased knowledge about factors that influence the treatment of people with difficult-to-treat anorexia nervosa\n2. To highlight the role of autonomy and patient participation in inpatient care of severe eating disorders\n3. To use the research results for clinical improvement work at Region Skåne Eating Disorders Center",[29,30],"NOT_YET_RECRUITING","2026-06-15",{"date":92,"type":46},"2026-06-16",{"date":94,"type":23},"2026-09",{"date":96,"type":23},"2029-12",{"name":98,"class":52},"Region Skane",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":106,"minAge":107,"maxAge":19,"enrollmentInfo":108,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100642373","sleep-quality-and-biomarkers-in-adolescent-girls-with-anorexia-nervosa-100642373","NCT07644728","Sleep Quality and Biomarkers in Adolescent Girls With Anorexia Nervosa","Sleep Architecture, Inflammatory and Hormonal Biomarkers, Psychopathology, and Quality of Life in Adolescent Girls With Anorexia Nervosa: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Female sex assigned at birth\n2. Age between 10 and 18 years (inclusive) at the time of study enrollment\n3. First-time diagnosis of anorexia nervosa according to ICD-10 criteria at the time of enrollment, including:\n\n   * Anorexia nervosa (F50.0)\n   * Atypical anorexia nervosa (F50.1)\n   * Eating disorder, unspecified (F50.9) with predominant restrictive or anorexic presentation\n4. Currently under the care of a child and adolescent psychiatrist at the Department of Psychiatry, University Hospital of Split (KBC Split), Croatia\n5. Enrolled in or eligible for the Day Hospital Program for Children and Adolescents at the Department of Psychiatry, KBC Split\n6. Ability to read and understand Croatian language sufficiently to complete self-report questionnaires\n7. Parent or legal guardian willing and able to provide written informed consent prior to any study procedure\n8. Participant willing and able to provide written assent prior to any study procedure\n9. Participant and parent\u002Fguardian willing to undergo all study procedures at both time points, including:\n\n   * Home polysomnography (NOX A1) at baseline and 12-month follow-up\n   * Completion of all self-report questionnaires at baseline and 12-month follow-up\n   * Fasting blood sampling at baseline and 12-month follow-up\n\nExclusion Criteria:\n\n1. Age younger than 10 years or older than 18 years at the time of enrollment\n2. Male sex assigned at birth\n3. Previous diagnosis of anorexia nervosa prior to current enrollment (i.e., recurrent or relapsing AN - this study enrolls first-diagnosis cases only)\n4. Anorexia nervosa currently in clinical remission at the time of enrollment\n5. Comorbid psychiatric diagnosis of any of the following:\n\n   * Intellectual disability (any severity, ICD-10: F70-F79)\n   * Autism spectrum disorder (ICD-10: F84)\n   * Schizophrenia spectrum or other psychotic disorder (ICD-10: F20-F29)\n   * Bipolar affective disorder, any type (ICD-10: F31)\n   * Substance use disorder, any substance (ICD-10: F10-F19)\n6. Severe or chronic somatic illness documented in medical history, including but not limited to:\n\n   * Central nervous system disorders (epilepsy, acquired brain injury, neurodegenerative disease, ICD-10: G00-G99)\n   * Chronic inflammatory or autoimmune disease (e.g., inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis)\n   * Primary endocrine disorder independent of AN (e.g., primary hypothyroidism, type 1 or type 2 diabetes mellitus, congenital adrenal hyperplasia)\n   * Active or history of malignancy\n   * Chronic renal or hepatic disease\n7. Use of any medication known to significantly alter sleep architecture or inflammatory biomarker levels that was initiated prior to study enrollment and is unrelated to the study treatment program, including:\n\n   * Benzodiazepines or z-drugs (zopiclone, zolpidem)\n   * Antipsychotic medications\n   * Systemic corticosteroids\n   * Immunosuppressive agents\n   * Melatonin or melatonin receptor agonists Medications initiated as part of the Day Hospital treatment program after enrollment will be documented and included as covariates in statistical analyses and do not constitute an exclusion criterion.\n8. Presence of an active somatic condition at the time of enrollment requiring acute inpatient medical treatment (e.g., severe electrolyte imbalance requiring intravenous correction, acute cardiac arrhythmia) that would preclude safe participation in the Day Hospital Program\n9. Physical or cognitive inability to cooperate with home polysomnography device placement or self-report questionnaire completion, as judged by the treating child and adolescent psychiatrist\n10. Simultaneous participation in another interventional clinical trial that could influence sleep parameters, nutritional status, inflammatory markers, or psychiatric outcomes.\n11. Absence of written informed consent from parent or legal guardian, or absence of written assent from the participant","FEMALE","10 Years",{"count":7,"type":23},"The purpose of this observational study is to systematically evaluate how a 12-month multimodal psychiatric treatment program affects sleep quality, inflammatory and hormonal biomarkers, eating disorder psychopathology, and health-related quality of life in adolescent girls (aged 10-18 years) diagnosed with anorexia nervosa.\n\nThe main questions it aims to answer are:\n\n* Do adolescent girls with anorexia nervosa have measurable changes in sleep patterns (total sleep time, sleep efficiency, REM sleep, deep sleep) compared to age- and sex-matched published values, and do these improve after 12 months of psychiatric treatment?\n* Are specific body markers (like NLR, CRP, vitamin D, and lipid profile) linked to how severe sleep problems, eating disorder symptoms, and treatment results are in this group?\n* To assess these outcomes, researchers will compare participants' baseline measurements to their own 12-month follow-up measurements to determine whether multimodal psychiatric treatment produces clinically meaningful improvements in sleep architecture, biomarker profiles, psychopathology, psychological flexibility, and quality of life.\n\nParticipants will:\n\n* Take-home sleep recordings with a wireless device (NOX A1) in their usual environment at the start and after 12 months of treatment.\n* Complete validated self-report questionnaires assessing sleep quality (PSQI), daytime sleepiness (ESS-CHAD for children and adolescents), eating disorder symptoms (EDE-Q), depression, anxiety, and stress (DASS-21), psychological flexibility (AFQ-Y8), and health-related quality of life (KIDSCREEN-52) at baseline and 12-month follow-up.\n* Give blood samples at the start and after 12 months for testing of inflammation markers, hormone levels, lipids, and anthropometric measurements.\n* Take part in a Day Hospital Program at the Department of Psychiatry, University Hospital of Split (KBC Split), Croatia, which includes Acceptance and Commitment Therapy, Cognitive Behavioral Therapy, individual counselling, family work, and medication if needed.",[30],[30,112,113,114,115,116,117],"Sleep Quality","Adolescents, Female","Eating Behaviour","Mental Health","Quality of life","Inflammatory markers","2026-06-08",{"date":120,"type":46},"2026-06-12",{"date":122,"type":23},"2026-05-30",{"date":124,"type":23},"2029-12-31",{"name":126,"class":52},"University of Split, School of Medicine",{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":24,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":53},"100424724","relapse-prevention-and-changing-habits-in-anorexia-nervosa-100424724","NCT04810624","Relapse Prevention and Changing Habits in Anorexia Nervosa","Optimizing Relapse Prevention and Changing Habits in Anorexia Nervosa","REACH+","Inclusion Criteria:\n\n* Diagnosis of Anorexia Nervosa at hospital admission\n* Medically Stable\n* Internet capability with videoconferencing\n* Weight restored (BMI \\> 19 kg\u002Fm2) at New York State Psychiatric Institute\n\nExclusion Criteria:\n\n* Current substance use or other comorbid disorder requiring specialized treatment\n* Pregnancy\n* Imminent risk of suicide\n* Serious medical illness\n* Daily psychotropic medication other than antidepressants (medications that are known effect weight are exclusionary, i.e. stimulants, olanzapine, mirtazapine)\n* Participation in outside psychotherapy or structured treatment program (support groups will be allowed). Individuals who are discharged on medications would need to have a non-study psychiatrist.","60 Years",{"count":137,"type":23},60,[26],"This study aims to optimize a treatment package for the relapse prevention treatment of AN. In the Preparation Phase, we examined accessibility and feasibility of the treatment package.\n\nIn the current Optimization Phase, we will identify which components of treatment contribute to positive outcomes after acute hospitalization. We will carefully evaluate maintenance of remission, measured by rate of weight loss and end-of-trial status.",[30],"2026-05-28",{"date":143,"type":46},"2026-06-01",{"date":145,"type":46},"2021-06-21",{"date":147,"type":23},"2027-06-01",{"name":149,"class":52},"New York State Psychiatric Institute",{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":106,"minAge":61,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":24,"phases":161,"briefSummary":162,"conditions":163,"keywords":168,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":178,"leadSponsor":179,"locationsCount":4},"100561684","fecal-microbiota-transplant-for-anorexia-nervosa-100561684","NCT06593366","Fecal Microbiota Transplant for Anorexia Nervosa","A Pilot Feasibility Randomized Controlled Trial of Fecal Microbiota Transplant for Adolescent Anorexia Nervosa","FMT-AN","Inclusion Criteria: All study subjects will have been diagnosed with AN (restricting type or binge eating\u002Fpurging type) by the primary physician on the ED team, as per standard approach. Study participants will:\n\n* Be 12-17 years-old at time of recruitment\n* Have capacity to consent\n* Be assigned female sex at birth (may be gender diverse)\n* Be active patients in the pediatric ED program at MCH\n* Have a weight that is \\\u003C85% of the Treatment Goal Weight, as determined by the treating physician\n\nExclusion Criteria: Potential study subjects will be excluded due to the following reasons:\n\n* Exposure to antibiotics within two weeks of study randomization\n* Initiation of new probiotics \u002F oral nutritional supplements within two weeks of randomization\n* Active pregnancy\n* Active psychosis or suicidal ideation\n* Other comorbidities that may affect weight or the gut microbiome including celiac disease, inflammatory bowel disease (or other conditions as determined by the study team)","17 Years",{"count":160,"type":23},20,[26],"The purpose of this pilot randomized-controlled trial is to determine whether Fecal Microbiota Transplant (FMT) treatment demonstrates feasibility, acceptability, and prelinary effectiveness among patients with anorexia nervosa (AN). Specifically, the investigators aim to compare changes in weight, gut microbiome, urine, blood biomarkers and mood symptoms between participants receiving the FMT intervention and placebo.",[164,30,165,166,167],"Anorexia Nervosa Restricting Type","Anorexia in Adolescence","Anorexia in Children","Anorexia",[169,170,171,172,173],"anorexia nervosa","fecal microbiota transplant","pilot study","randomized controlled trial","feasibility","2026-05-22",{"date":176,"type":46},"2026-05-27",{"date":143,"type":23},{"date":147,"type":23},{"name":180,"class":52},"Hamilton Health Sciences Corporation",{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":106,"minAge":188,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":24,"phases":192,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":53},"100352938","phase-2-transdermal-estrogen-in-women-with-anorexia-nervosa-100352938","NCT03875378","Transdermal Estrogen in Women With Anorexia Nervosa","Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia Nervosa","Inclusion Criteria:\n\n1. Female\n2. 19-45 years of age\n3. DSM-5 psychiatric criteria for anorexia nervosa\n4. \\\u003C85% of ideal body weight as defined by the 1983 Metropolitan Life Insurance Height and Weight Tables\n5. Amenorrhea\n6. T-score of \\\u003C -1.0 at spine or hip\n\nExclusion Criteria:\n\n1. Diseases known to affect bone metabolism, including untreated thyroid dysfunction, vitamin D deficiency, Cushing's syndrome, diabetes mellitus or renal insufficiency (eGFR \\\u003C 60)\n2. Personal history of venous or arterial clot\n3. History of stroke or myocardial infarction\n4. History of hypercoagulable disorder\n5. Personal history or history of a first-degree relative with breast cancer\n6. History of hereditary angioedema\n7. Any medication known to affect bone metabolism, including systemic glucocorticoids within three months of the baseline visit, depot medroxyprogesterone within 6 months of the baseline visit, oral bisphosphonates within one year of the baseline visit or IV bisphosphonates within three years of the baseline visit\n8. Bone fracture within the prior 12 months\n9. Serum potassium \\\u003C 3.0 meq\u002FL, serum ALT \\> 3 times the upper limit of normal or Hemoglobin \\\u003C 10 g\u002FdL\n10. Fasting serum triglyceride level \\> 150 mg\u002FdL\n11. Pregnant or breastfeeding (or desiring pregnancy within the next 18 months)\n12. Active substance abuse\n13. Elevated PTH level\n14. 25-OH vitamin D level \\\u003C 20 ng\u002FmL\n15. Low phosphorus level","19 Years","45 Years",{"count":191,"type":23},66,[193],"PHASE2","Randomized, placebo-controlled study investigating the use of physiologic, transdermal estrogen for low bone mass in adult women with anorexia nervosa.",[30],[197,198],"Bone mineral density","Estrogen","2026-05-14",{"date":201,"type":46},"2026-05-18",{"date":203,"type":46},"2020-08-28",{"date":205,"type":23},"2028-12-31",{"name":207,"class":52},"Pouneh K. Fazeli, MD",{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":18,"minAge":216,"maxAge":19,"enrollmentInfo":217,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":53},"100556673","speech-groups-for-children-living-with-a-sibling-who-suffers-from-anorexia-nervosa-100556673","NCT06528158","Speech Groups for Children Living With a Sibling Who Suffers From Anorexia Nervosa","Sibling Group for Children and Teenagers Living With a Sibling Who Suffers From Anorexia Nervosa: a Pilot Acceptability Study","EMA-FRaM","* inclusion criteria : Sibling presenting a DSM (Diagnostic and Statistical Manual)-5 of Mental Disorders diagnosis of AN, and engaged in inpatient or outpatient healthcare\n* exclusion criteria :\n\n  * (1) Opposition from the participant and\u002For from their legal representatives.\n  * (2) Non-fluent French speaker\n  * (3) Clinical presentation not compatible with the group sessions","8 Years",{"count":218,"type":23},24,"Anorexia nervosa (AN) is a complex mental disease with a huge impact on the patient's siblings life and well-being. Based on literature, group interventions for siblings of children suffering from a chronic disease could provide an effective support. A few have been studied, and even fewer exist for siblings of children with AN.",[30],[222,223,224,225,226],"siblings","groups","children","teenagers","acceptability","2026-05-07",{"date":229,"type":46},"2026-05-12",{"date":231,"type":46},"2025-01-02",{"date":233,"type":23},"2026-08-02",{"name":235,"class":52},"University Hospital, Toulouse",{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":244,"sex":106,"minAge":19,"maxAge":189,"enrollmentInfo":245,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":247,"conditions":248,"keywords":249,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":53},"100637421","hormonal-and-metabolic-signatures-in-human-hypothalamic-neurons-in-anorexia-nervosa-100637421","NCT07580209","Hormonal And Metabolic Signatures In Human Hypothalamic Neurons In Anorexia Nervosa","HOrmone Profiles and Energy Metabolism Signatures in Hypothalamic-like Neurons Generated From Patients With Anorexia Nervosa","HOPE","Inclusion Criteria:\n\nFemale participants aged 18-45 years (premenopausal) Diagnosis of severe and enduring anorexia nervosa (illness duration ≥7 years, with documented functional impairment and non-response to appropriate treatments) Current BMI ≤18.5 kg\u002Fm² or documented BMI ≤18.5 kg\u002Fm² within the past 12 months Ability to provide informed consent Sufficient proficiency in the study language (German)\n\nFor healthy controls:\n\nFemale participants aged 18-45 years BMI between 18.5 and 24.9 kg\u002Fm² No current or past diagnosis of eating disorders No major psychiatric disorder Ability to provide informed consent\n\nExclusion Criteria:\n\nPregnancy or breastfeeding Severe medical comorbidities affecting metabolic or central nervous system function (e.g., uncontrolled endocrine, hepatic, renal, or cardiovascular diseases) Current psychosis or acute suicidality Current serious non-suicidal self-injury Substance dependence Use of medications that substantially alter metabolic or endocrine function (including high-dose systemic corticosteroids, hormonal contraceptives, or psychotropic medications such as antidepressants, antipsychotics, mood stabilizers, or anxiolytics) Positive status for HIV, hepatitis B (HBV), or hepatitis C (HCV) Intellectual disability impairing the ability to provide informed consent Insufficient proficiency in the study language",true,{"count":246,"type":23},10,"The goal of this observational study is to investigate cellular mechanisms of neuroendocrine and metabolic signaling in adult women with anorexia nervosa (AN) compared to healthy controls. The primary purpose is to understand how hypothalamic-like neurons derived from patient samples respond to metabolic hormones and regulate energy homeostasis.\n\nThe main questions it aims to answer are:\n\nDo hypothalamic-like neurons derived from individuals with AN show altered responsiveness to key metabolic hormones compared to neurons derived from healthy controls? Are there differences in cellular metabolism, gene expression profiles, and neuronal activity that reflect disease-relevant neuroendocrine dysfunction? Researchers will compare patient-derived cellular models from individuals with AN to those generated from matched healthy control participants to determine whether differences in hormone responsiveness, metabolic function, and neuronal signaling can be identified.\n\nParticipants will:\n\nAttend a single study visit at a recruiting clinical site Provide a small peripheral blood sample Undergo basic clinical assessment and anthropometric measurements Collected samples will be coded at the recruiting sites and transferred to a central research laboratory, where they will be used to generate induced pluripotent stem cells (iPSCs) and differentiate them into hypothalamic-like neurons. All experimental analyses are conducted in vitro and do not involve any intervention or treatment administered to participants.",[30],[30,29,250,251],"Hypothalamus","Neuroendocrinology","2026-05-05",{"date":229,"type":46},{"date":255,"type":46},"2026-04-30",{"date":257,"type":23},"2028-12",{"name":259,"class":52},"Maria Miletta",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":106,"minAge":19,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":24,"phases":270,"briefSummary":272,"conditions":273,"keywords":274,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":281,"leadSponsor":282,"locationsCount":284},"100640622","phase-1-reestablishing-normal-gut-brain-interaction-in-anorexia-nervose-with-normal-gut-microbiota-100640622","NCT07574892","Reestablishing Normal Gut-brain Interaction in Anorexia Nervose With Normal Gut Microbiota","Reestablishing Normal Gut-Brain Interaction in Anorexia Nervosa With Normal Gut Microbiota: Restart","Restart","Inclusion Criteria:\n\nAge 18 years or more Starting outpatient psychotherapy for anorexia nervosa At least one failed qualified treatment attempt\n\nExclusion Criteria:\n\nAge below 18 years BMI below 16 kg\u002Fm2 Significant electrolyte disturbances Other signs of medical instability Presence of systemic disease, Immune deficiency Treated with immune-modulating medication Pregnancy Planning pregnancy Lactations Having undergone abdominal surgery (with the exception of appendectomy, cholecystectomy, caesarian section and hysterectomy) severe psychiatric disease (except anorexia nervosa) Use of probiotics or treatment with antibiotics within 8 weeks prior to study entry.",{"count":269,"type":23},36,[271],"PHASE1","In this pilot study 36 patients with anorexia nervosa (AN) will be randomized to either treatment with psychotherapy as usual (TAU) or TAU plus fecal microbiota transplantation (FMT). The transplantation will be performed when refeeding has started. Patients randomized to TAU+FMT will choose either capsules or gastroscopy as source of FMT. One week after FMT gut microbiota will be collected and analyzed and compared with microbiota composition at baseline. The two groups are then followed during psychotherapy to assess whether it is feasible to give FMT during psychotherapy to study the effects on outcome. In addition, this pilot study is aiming at paving the way for performing larger studies to assess whether FMT improves outcome from psychotherapy when given in combination with psychotherapy in patients with AN.",[30],[275,276,277],"Anorexia nervosa","Fecal microbiota transplantation","Psychotherapy",{"date":279,"type":46},"2026-05-08",{"date":143,"type":23},{"date":257,"type":23},{"name":283,"class":52},"Haukeland University Hospital",4,{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":18,"minAge":292,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":24,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":300,"leadSponsor":302,"locationsCount":53},"100638768","incorporating-narrative-into-the-treatment-of-youth-with-anorexia-nervosa-virtual-100638768","NCT07579442","Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa (Virtual)","Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa","Inclusion Criteria:\n\n* 16-25 years old\n* have a DSM-5 diagnosis of AN (confirmed by the UCSF Eating Disorders Program clinical team),\n* currently engaged in outpatient eating disorder treatment, ensuring medical stability and capacity for a group-based intervention\n* English fluency to engage in reflective writing and discussions\n* Cognitive ability to meaningfully participate in narrative-based exercises\n\nExclusion Criteria:\n\n* Currently medically unstable or require inpatient hospitalization\n* History of psychosis, schizophrenia spectrum disorder, bipolar disorder, or personality disorder\n* Severe neurocognitive impairment that would prevent engagement with the intervention\n* Active suicidal ideation or non-suicidal self-injury within the past two months\n* Insufficient English proficiency to participate in group discussions and writing exercises","16 Years","25 Years",{"count":246,"type":23},[26],"The goal of this clinical trial is to evaluate whether a narrative medicine (NM) curriculum can enhance self-expression, reflection, and resilience in adolescents and young adults with anorexia nervosa.\n\nThe main questions it aims to answer are:\n\n* Does participation in an NM curriculum improve self-expression and reflection in individuals with anorexia nervosa?\n* Does engaging in creative writing and group discussion promote resilience and emotional processing in this population?\n\nParticipants will be 16-25 years old, medically stable for outpatient eating disorder therapy, and actively engaged in treatment. Those with active suicidal ideation, recent non-suicidal self-injury, or a co-occurring personality disorder will not be eligible.\n\nParticipants will:\n\n* Attend six weekly workshops focused on themes such as self-definition, kindness, resilience, and possibility\n* Engage in close reading of visual or written texts\n* Complete creative writing exercises in response to prompts\n* Participate in group discussions and sharing\n\nAn optional capstone reading event will provide a supportive space for participants to share their work with peers, loved ones, and providers, fostering connection and community.\n\nThis study aims to explore the role of narrative medicine in eating disorder treatment and assess its potential benefits for psychological well-being and self-expression.",[30],{"date":229,"type":46},{"date":45,"type":23},{"date":301,"type":23},"2027-07-01",{"name":303,"class":52},"University of California, San Francisco",{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":18,"minAge":312,"maxAge":19,"enrollmentInfo":313,"targetDuration":4,"studyType":24,"phases":314,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":53},"100639620","phase-3-pediatric-prolonged-release-melatonin-for-sleep-disturbances-in-children-and-adolescents-with-anorexia-nervosa-melsom-anorexia-100639620","NCT07576764","Pediatric Prolonged-Release Melatonin for Sleep Disturbances in Children and Adolescents With Anorexia Nervosa (MELSom-ANOREXIA)","Efficacy of Pediatric Prolonged-Release Melatonin (PedPRM) Treatment in Children and Adolescents With Impaired Sleep and Anorexia Nervosa (AN)","MELSomAnorexia","INCLUSION CRITERIA\n\nParticipants aged 6 to 18 years, inclusive, with a diagnosis of Anorexia Nervosa (AN) according to DSM-5 criteria Presence of a sleep problem for at least 1 month, defined as ≤ 6 hours of continuous sleep and\u002For ≥ 0.5 hours sleep latency from lights-off on 3 out of 5 nights, based on participant report (with or without parental assistance according to age), confirmed at D0 by 2-week sleep diary No response to at least 4 weeks of sleep hygiene Negative pregnancy test at baseline, prior to randomization, for female participants of childbearing potential Women of childbearing potential must agree to use a highly effective method of contraception during the study treatment period and for at least 4 weeks after the last dose of study treatment Written informed consent obtained in accordance with the participant's legal status and applicable regulations Affiliation to a social security system or equivalent\n\nEXCLUSION CRITERIA\n\nKnown diagnosis of another significant sleep disorder (e.g. moderate to severe sleep apnea) Use of prohibited medication (z-drugs, melatonin agonist, benzodiazepine, phenylpiperazine class, clomethiazole) or melatonin within 2 weeks prior to screening Declared allergy to melatonin, lactose, or any excipient included in the therapeutic units Pregnant or breastfeeding female participants Unresponsiveness to previous prolonged-release melatonin within the 2 years prior to the study Start of cognitive behavioural therapy (CBT) targeting sleep disturbances or mood disorders within 6 weeks before study inclusion Trans-meridian travel (\\> 2 time zones) within the month before the start of the study Patient under legal protection regimen","6 Years",{"count":63,"type":23},[315],"PHASE3","Sleep disturbances are reported by more than 50% of patients with Anorexia Nervosa (AN) and are associated with increased AN severity, psychiatric comorbidities, and poorer quality of life. To date, no pharmacological treatment has been approved or recommended for sleep disorders in children and adolescents with AN. Many drugs are currently prescribed off-label for their sedative side effects, without proven safety or efficacy in this population.\n\nPediatric prolonged-release melatonin (PedPRM, Slenyto®) is the only melatonin formulation approved by the European Medicines Agency (EMA) for chronic insomnia in children aged 2 to 18 years with neurodevelopmental disorders. Its excellent safety profile, absence of tolerance, and long-acting formulation make it a prime candidate for treating sleep disturbances in children and adolescents with AN.\n\nMELSom-ANOREXIA is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb trial. Its primary objective is to assess the efficacy of PedPRM compared to placebo in improving Total Sleep Time (TST) in children and adolescents aged 6 to 18 years with AN and impaired sleep.\n\nParticipants are randomized into two groups: the experimental group receives PedPRM (2 mg or 5 mg depending on response at Day 22) and the control group receives a matching placebo, both administered 0.5 to 1 hour before habitual bedtime for 13 weeks. Sleep is assessed by Sleep Diary and actigraphy. Secondary outcomes include other sleep parameters, AN severity (BMI, EDI-2, EDE-Q), associated symptoms (anxiety, depression, physical activity, executive function, emotionality), and quality of life. Melatonin secretion profiles and specific subgroups (ASD traits, early-onset AN) are also explored.\n\nThe study includes a 2-week run-in period (D-14 to D0) for baseline sleep assessment, followed by 13 weeks of treatment, with visits at D0, D22, and D93. A total of 120 participants will be enrolled across 7 French pediatric psychiatry centers over 24 months.",[30,318],"Sleep Disorders in Children",[320],"anorexia","2026-05-04",{"date":279,"type":46},{"date":324,"type":23},"2026-09-01",{"date":326,"type":23},"2029-01-01",{"name":328,"class":52},"Assistance Publique Hopitaux De Marseille",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":293,"maxAge":189,"enrollmentInfo":336,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":338,"conditions":339,"keywords":341,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":351},"100600489","neural-correlates-of-autistic-individuals-with-anorexia-nervosa-100600489","NCT07098156","Neural Correlates of Autistic Individuals With Anorexia Nervosa","Neuroanatomical Differences Associated With Anorexia Nervosa and Masking Behaviour in Autistic Individuals","Inclusion Criteria:\n\nHealthy Autistic Individuals (Autistic Controls) must:\n\n* Be aged 25-45 years\n* Be Autistic (clinically diagnosed and\u002For have an Autism Quotient (AQ-10) score of ≥6)\n* Be able to provide informed consent for the study\n* Be able to read, understand and respond to questionnaires in English\n* Have no history of an eating disorder\n* Willing to have an MRI scan in Aberdeen\n\nAutistic Individuals with anorexia nervosa must:\n\n* Be aged 25-45 years\n* Be Autistic (clinically diagnosed and\u002For have an AQ-10 score of ≥6)\n* Be able to provide informed consent to the study\n* Be able to read, understand and respond to questionnaires in English\n* Have a diagnosis of anorexia nervosa or a body mass index of \\\u003C18.5\n* Willing to have an MRI scan in Aberdeen\n\nExclusion Criteria:\n\nIndividuals are not eligible for the study if they:\n\n* Are aged \\\u003C25 or \\>45 years\n* Are not Autistic or not clinically diagnosed as Autistic and have an AQ-10 score of \\\u003C6\n* Are diagnosed with an eating disorder other than anorexia nervosa\n* Have a history of brain injury (e.g., stroke)\n* Be unable to provide informed consent for the study\n* Have contraindications to MRI scanning, such has implantable cardiac devices\n* Are unable to read, understand and respond to questionnaires in English\n* As participants will need to consent to the study and complete questionnaires by themselves, individuals with intellectual disability will be excluded from this study",{"count":337,"type":23},50,"Masking is a behaviour or strategy used by many Autistic people to appear non-Autistic and blend in with a neurotypical society. The goal of this observational study is to understand the relationship between masking, anorexia nervosa symptoms and brain structure in Autistic people. The main questions this study aims to answer are:\n\n* Do Autistic individuals with anorexia nervosa show differences in structure or function of the brain relation to Autistic individuals without anorexia nervosa?\n* Do Autistic individuals with anorexia nervosa display higher levels of masking than Autistic individuals without anorexia nervosa?\n* Are there indeed relationships between levels of masking, anorexia nervosa symptoms and brain structure in Autistic people?\n\nResearchers will compare Autistic people without anorexia nervosa to Autistic people with anorexia nervosa to see if there are differences between groups. Participants will:\n\n* Complete a series of questionnaires focused on eating disorder symptoms, autistic traits, autistic masking and psychological well-being\n* Undergo an MRI scan at the Aberdeen Royal Infirmary",[340,30],"Autism",[342,343],"MRI","Magnetic Resonance Imaging",{"date":252,"type":46},{"date":346,"type":46},"2025-07-15",{"date":348,"type":23},"2026-07-31",{"name":350,"class":52},"University of Aberdeen",2,{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":24,"phases":362,"briefSummary":363,"conditions":364,"keywords":365,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":53},"100528867","improving-the-treatment-of-anorexia-nervosa-in-children-through-virtual-reality-body-exposure-100528867","NCT06166355","Improving the Treatment of Anorexia Nervosa in Children Through Virtual Reality Body Exposure","EOAN-VR-ABM","Inclusion Criteria:\n\n* Patients with a primary diagnosis of anorexia nervosa (DSM-V)\n* Patients below 14 years old\n* Patients with BMI \\\u003C18.5\n* Subsyndromal patients will also be included\n\nExclusion Criteria:\n\n* Visual deficits\n* Epilepsy or neuroleptic medication\n* Psychotic disorder\n* Bipolar disorder\n* Medical complications\n* Pregnancy\n* Clinical cardiac arrhythmia","14 Years",{"count":361,"type":23},108,[26],"The age of onset of anorexia nervosa has been progressively decreasing in recent years. Also, the prevalence rates of childhood anorexia in many countries have grown significantly. This increase was already observed before the COVID-19 pandemic, but the confinements and the stress derived from them have caused this increase to accelerate. As in adolescent and adult patients, in childhood anorexia some of the core signs and symptoms are an extreme fear of gaining weight and avoidance of food. The consequences of the early-onset of anorexia can be very important since the maturation of the organism is more incomplete in children than in adolescents. Weight loss can have very severe consequences, since in children the percentage of body fat is lower. On the other hand, hormonal disorders derived from food deprivation also have very severe consequences for the development of different organs. General physical development and growth can be affected, with consequences such as not being able to reach normal height. The research carried out to date on the efficacy of treatments for childhood anorexia is very scarce. There are no specific treatment strategies or settings for children with anorexia, and little research has been done to tailor treatment for younger patients. Given the need to explore new treatments for anorexia nervosa specifically aimed at children, the objective of this project is to develop a program to carry out exposure to one's own body through virtual reality, gradually, with progressive increases in size until achieving a healthy weight. In the virtual exposure, patients will observe the image of an avatar in a mirror for the time necessary in each session to produce the reduction of the anxiety response. The avatars that will be developed for this purpose will have a physical constitution corresponding to children under 14 years of age, and physical proportions equivalent to those of each patient. The positive results obtained with a previous version of this treatment originally developed for adolescents and adults suggest that its adaptation to children can open new ways for exploring effective treatments for childhood anorexia.",[30],[366,367,368,369,370],"Attentional Bias","Virtual Reality","Eye-Tracking","Body exposure procedure","Attentional bias modification training",{"date":279,"type":46},{"date":373,"type":46},"2024-07-01",{"date":375,"type":23},"2026-12-30",{"name":377,"class":52},"University of Barcelona",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":386,"enrollmentInfo":387,"targetDuration":4,"studyType":24,"phases":388,"briefSummary":389,"conditions":390,"keywords":395,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":53},"100531301","targeting-social-function-in-anxiety-and-eating-disorders-100531301","NCT06198023","Targeting Social Function in Anxiety and Eating Disorders","Targeting Social Function to Improve Outcomes in Anxiety and Eating Disorders","SF","Inclusion Criteria:\n\n* In the past 12 months, has met DSM-5 criteria met for an eating disorder (Anorexia Nervosa, Atypical Anorexia Nervosa, Bulimia Nervosa, Avoidant-Restrictive Food Intake Disorder, or Other Specified Feeding or Eating Disorder) and\u002For an anxiety disorder (Generalized Anxiety Disorder, Social Anxiety Disorder)\n* Between the ages of 18-30\n\nExclusion Criteria:\n\n* Current inpatient or residential treatment\n* Medical instability or safety\u002Fsuicide risk as determined by the PI","30 Years",{"count":137,"type":23},[26],"Social processing and cognition are often altered in patients with eating disorders. The goal of this clinical trial is to assess two different social therapeutic interventions -- one educational, one interactive -- for their effectiveness in improving clinical outcomes in patients with eating disorders. Patients in both interventions will receive education about social function in eating disorders, but those in the interactive treatment group will complete an additional collaborative art task.\n\nParticipants will:\n\n* attend a baseline study visit to complete clinical interviews, cognitive testing, and behavioral tasks\n* complete a pre-intervention assessment with questionnaires\n* attend eight sessions of their assigned treatment group over the course of 12 weeks\n* complete three virtual follow-up assessments 4, 8, and 12 months from their baseline\n* attend a final study visit to repeat some clinical interviews, cognitive testing, and behavioral tasks\n\nResearchers will compare changes in eating disorder, mood, and anxiety symptoms as well as test results from baseline and final study visits for each group to see if\n\n* patients can be treated effectively with education alone or if an interactive group component produces additional benefits\n* cognitive and behavioral task performance are associated with recovery or illness state.",[29,30,31,391,392,33,393,394],"Atypical Anorexia Nervosa","Purging (Eating Disorders)","Social Anxiety Disorder","Generalized Anxiety Disorder (GAD)",[396,397,398,399,400,401,402,403],"social function","social cognition","social processing","psychoeducation","group therapy","group intervention","art therapy","social anxiety","2026-04-28",{"date":252,"type":46},{"date":407,"type":46},"2024-02-28",{"date":409,"type":23},"2028-09",{"name":411,"class":52},"University of Texas Southwestern Medical Center",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":244,"sex":106,"minAge":19,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":53},"100559629","avoidance-driven-decision-making-and-learning-in-anorexia-nervosa-and-bulimia-nervosa-100559629","NCT06566612","Avoidance-driven Decision Making and Learning in Anorexia Nervosa and Bulimia Nervosa","Inclusion Criteria:\n\nEating Disorder Group:\n\n* Between the ages of 18 and 39 years old\n* Meet DSM-V criteria for anorexia nervosa or bulimia nervosa\n\nHealthy Controls:\n\n* Between the ages of 18 and 39 years old\n* Have maintained 85% to 120% ideal body weight since menarche\n\nExclusion Criteria:\n\n* Psychotic illness\u002Fother mental illness requiring hospitalization\n* Current dependence on drugs or alcohol defined by DSM IV criteria. Additionally, positive test results for drug use on the day of the scan, apart of marijuana, will result in cancelling or rescheduling the scan because acute use will impact MRI measures.\n* Physical conditions (e.g. diabetes mellitus, pregnancy) known to influence eating or weight\n* Neurological disorder, neurodevelopmental disorder, or history of head injury with \\>30 min loss of consciousness\n* Any contraindication to undergoing an MRI\n* Primary obsessive compulsive disorder or primary major depressive disorder\n\nAdditional Exclusion Criteria for ED Group:\n\n* If taking other psychotropic medication, any change in dosage in the 2 weeks before scanning\n\nAdditional Exclusion Criteria for Healthy Control Group:\n\n* Meet criteria for the diagnosis of any psychiatric disorder currently\n* Any history of binge eating or purging behaviors, including self-induced vomiting, laxative or diuretic misuse\n* Use of any psychoactive or other medication known to affect mood or concentration in the last 3 months","39 Years",{"count":420,"type":23},78,"The purpose of this study is to investigate areas of the brain responsible for avoidance learning in adults with eating disorders using brain imaging techniques, computer tasks, and self-report questionnaires and interviews. The investigators will study changes in brain activity using a procedure called functional magnetic resonance imaging (fMRI). This study will include 78 women with an eating disorder (26 with anorexia nervosa \\[AN\\], 26 with bulimia nervosa \\[BN\\]) and 26 healthy controls (HC) aged 18-39.\n\nAim 1: Evaluate behavioral differences in active and passive avoidance learning in eating disorders and associations with symptoms.\n\nAim 2: Evaluate whether corticostriatal and limbic-prefrontal fMRI BOLD response associated with avoidance learning differs in eating disorders relative to healthy controls and relates to symptoms.\n\nAim 3: Evaluate whether functional connectivity of avoidance learning neural circuity differs in eating disorders relative to healthy controls.",[31,30],"2026-04-27",{"date":425,"type":46},"2026-05-01",{"date":427,"type":46},"2024-08-01",{"date":429,"type":23},"2027-07-31",{"name":431,"class":52},"University of California, San Diego",{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":244,"sex":106,"minAge":19,"maxAge":418,"enrollmentInfo":438,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":53},"100443606","incentive-processing-and-learning-in-anorexia-nervosa-and-bulimia-nervosa-100443606","NCT05056597","Incentive Processing and Learning in Anorexia Nervosa and Bulimia Nervosa","Inclusion Criteria:\n\nEating Disorder Group:\n\n* Between the ages of 18 and 39 years old\n* Meet DSM-V criteria for AN-R, AN-BP, or BN\n\nHealthy Control Group:\n\n* Between the ages of 18 and 39 years old\n* Have maintained 85% to 120% ideal body weight since menarche\n\nExclusion Criteria:\n\nAll Groups:\n\n* Psychotic illness\u002Fother mental illness requiring hospitalization\n* Current dependence on drugs or alcohol defined by DSM IV criteria. Additionally, positive test results for drug use on the day of the scan, apart of marijuana, will result in cancelling or rescheduling the scan because acute use will impact MRI measures.\n* Physical conditions (e.g. diabetes mellitus, pregnancy) known to influence eating or weight\n* Neurological disorder, neurodevelopmental disorder, or history of head injury with \\>30 min loss of consciousness\n* Any contraindication to undergoing an MRI\n* Primary obsessive compulsive disorder or primary major depressive disorder\n\nAdditional Exclusion Criteria for ED Group:\n\n-If taking other psychotropic medication, any change in dosage in the 2 weeks before scanning\n\nAdditional Exclusion Criteria for Healthy Control Group:\n\n* Meet criteria for the diagnosis of any psychiatric disorder currently\n* Any history of binge eating or purging behaviors, including self-induced vomiting, laxative or diuretic misuse\n* Use of any psychoactive or other medication known to affect mood or concentration in the last 3 months",{"count":439,"type":23},252,"The purpose of this study is to investigate areas of the brain responsible for 'liking', 'wanting', and learning in adults with eating disorders using brain imaging techniques, computer tasks, a test meal, and self-report questionnaires and interviews. The investigators will study changes in brain activity using a procedure called functional magnetic resonance imaging (fMRI). This study will include 252 women with an eating disorder (63 AN-restricting type (AN-R), 63 AN-binge eating\u002Fpurging type (AN-BP), 63 bulimia nervosa (BN)) and 63 healthy controls (HC) aged 18-39.\n\nAim 1: To examine neural differences in 'liking' and 'wanting' in ED relative to HC.\n\nAim 2: To examine differences in instrumental learning for reward and punishment in ED relative to HC.\n\nAim 3: To examine how 'liking' and 'wanting' drive instrumental learning in ED and predict clinical symptoms at baseline and 1 year later.\n\nExploratory Aim: To explore the associations of dopamine function, as measured by neuromelanin MRI (NM-MRI), with ED diagnosis and brain response to 'liking', 'wanting', and learning.",[30,31],{"date":404,"type":46},{"date":444,"type":46},"2022-05-26",{"date":446,"type":23},"2027-01",{"name":431,"class":52},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":18,"minAge":359,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":24,"phases":459,"briefSummary":460,"conditions":461,"keywords":462,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":4},"100427477","rtms-for-aneroxia-nervosa-in-youth-100427477","NCT04846517","rTMS for Aneroxia Nervosa in Youth","Multilocus Repetitive Transcranial Magnetic Stimulation for Anorexia Nervosa (MULTI-REX): A 4-week Open-Trial Pilot Study","MULTI-REX","Inclusion Criteria:\n\n1. youth aged 14-24 with DSM-5 AN-restricting (ANR) or AN-binge-eating-purging (ANBP) type as determined by the MINI-KID\u002FMINI and clinical interview;\n2. YBC-EDS score≥16,\n3. baseline CGI-S score ≥4,\n4. English speaking (as this complement of questionnaires are available in English)\n5. on stable psychotropic medication (if any) for the preceding 4 weeks (i.e., SSRIs, atypical antipsychotics and benzodiazepines of doses \\\u003C1 mg lorazepam equivalent daily),\n6. medically stable, as determined by their treating clinician, and\n7. not deemed to be at high risk of imminent suicidal behavior by initial study psychiatrist assessment and referring provider\u002Fteam, and no endorsement of items 4 or 5 on the Severity of Ideation Subscale of the C-SSRS.\n8. For women: not currently pregnant and on reliable birth control if sexually active (as the effects of rTMS on the unborn fetus are unknown).\n\nExclusion Criteria:\n\n1. a lifetime history of psychosis, mania, or seizure disorder\n2. active suicidality as determined by clinical assessment by MD or PhD, and endorsement of items 4 or 5 on the Severity of Ideation Subscale of the C-SSRS.\n3. unstable neurological disorder,\n4. metal in head\u002Feye,\n5. inability to tolerate MRI,\n6. at high risk of alcohol withdrawal or substance intoxication,\n7. diagnosis of pervasive development disorder,\n8. medical instability as determined by primary care provider and\u002For referring clinician (i.e., unstable electrolytes in the setting of worsening binge-eating\u002Fpurging, cardiac arrhythmias requiring Holter or other intensive monitoring),\n9. For women: pregnant or not using a reliable form of birth control.","24 Years",{"count":458,"type":23},45,[26],"This study will examine the feasibility of off-label multilocus repetitive transcranial magnetic stimulation (rTMS) for symptoms of Anorexia Nervosa in participants between the ages of 14-24. rTMS is a non-invasive, brain-based intervention that uses magnets to deliver energy to the brain. The investigators will also see if patients receiving multilocus rTMS show any improvements in their eating disorder, mood, anxiety, and obsessions and compulsions (if present). Participants will receive daily intervention with off-label multilocus rTMS for 20 total treatments. Participants will also be asked to complete mental health and well-being surveys, physical measurements, and 2 brain imagining scans (MRIs) at baseline, and at study end. The investigators will also ask participants to complete surveys are 1-month and 3-months after the final rTMS session. The target enrollment for this study is 45 participants.",[30],[463,464],"AN","TMS","2026-04-21",{"date":467,"type":46},"2026-04-24",{"date":469,"type":23},"2027-01-30",{"date":471,"type":23},"2030-01-01",{"name":473,"class":52},"University of California, Los Angeles",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":18,"minAge":292,"maxAge":189,"enrollmentInfo":481,"targetDuration":4,"studyType":24,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":53},"100562581","therapeutic-ketogenic-diet-in-partial-hospital-program-php-anorexia-nervosa-100562581","NCT06605027","Therapeutic Ketogenic Diet in Partial Hospital Program (PHP) Anorexia Nervosa","Therapeutic Ketogenic Diet to Treat Anorexia Nervosa-Specific Cognitions and Behaviors - Currently Ill Individuals in PHP Level of Care and Comparison With Standard of Care","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\u002Fparental permission form\n2. Provision of signed and dated assent form if the subject is a minor\n3. Stated willingness to comply with all study procedures and availability for the duration of the study\n4. Persons, aged 16 to 45 years\n5. Current anorexia nervosa diagnosis according to DSM-5 criteria\n6. An elevated EDE-Q global score of 2.09 or greater\n7. The following types of psychiatric medications are allowed: antidepressant, anxiolytic, atypical antipsychotic, mood stabilizers\n8. English is primary spoken language\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Electrolyte, blood count, kidney function or liver function abnormalities\n3. Psychosis\n4. Neurocognitive disorders including dementias or traumatic brain injury that is symptomatic\n5. Current alcohol use disorder (AUD) or substance use disorder (SUD) according to DSM-5 criteria\n6. Uncontrolled hypertension\n7. Hepatic impairment (Class-Pugh b or c)\n8. Diabetes mellitus\n9. Family history of porphyria\n10. History of recent heart attack, vascular disease, or any other current acute medical conditions as determined by the principal investigator\n11. Inability or unwillingness to adhere to the TKD diet for the duration of the study\n12. Blind or illiterate individuals",{"count":63,"type":23},[26],"This will be a 14-week longitudinal study with an open design. A total of 120 individuals will be recruited for an end goal of 60 individuals with anorexia nervosa (AN) who are currently in high level of care treatment at the UCSD Eating Disorder Center partial hospital program (PHP) or intensive outpatient (IOP). Forty individuals will be recruited to the TKD and 20 will be treated with treatment as usual with respect to food intake. The age range will be between 16 and 45 years. All study participants will be carefully assessed and will complete rater and self-assessments at the being at the end of the study period. While in the treatment program, the TKD group will receive catered ketogenic meals via a meal service. After discharging from program, participants will have the option to continue with the meal service or cook for themselves. After establishing ketosis, study participants will continue TKD for 12 weeks. All study participants will be followed over three, six, and twelve months after enrolling in the study, whether initiating TKD or being in the treatment as usual arm. This follow-up procedure will help determine whether symptom improvement is stable or worsens in individuals who choose to continue or discontinue the TKD intervention and in relation to the control group. After ketosis induction over two weeks, study participants will be assessed weekly for ketosis and mood, anxiety, and eating disorder symptoms over twelve weeks.",[30],"2026-04-20",{"date":487,"type":46},"2026-04-23",{"date":489,"type":23},"2027-01-01",{"date":491,"type":23},"2028-08-31",{"name":431,"class":52},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":244,"sex":18,"minAge":19,"maxAge":189,"enrollmentInfo":500,"targetDuration":4,"studyType":24,"phases":502,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":53},"100557637","ketogenic-diet-and-brain-response-in-anorexia-nervosa-100557637","NCT06540703","Ketogenic Diet and Brain Response in Anorexia Nervosa","Ketogenic Diet in Weight Recovered Anorexia Nervosa to Normalize Brain Metabolism and Persistent Eating Disorder Psychopathology","Inclusion Criteria:\n\nWeight Recovered Anorexia Nervosa (wrAN)\n\n* Age 18-45 years old\n* Male and Female sexes\n* All ethnic backgrounds\n* History of restricting-type anorexia nervosa (AN) according to DSM-5 criteria\n* Weight recovered with a body mass index \\> 17.5 for at least one month at the time of study\n* Elevated eating disorder-relevant behaviors on the Eating Disorders Inventory-3 and the Eating Disorder Examination Questionnaire\n\nHealthy Control Group\n\n* Age 18-45 years old\n* Male and Female sexes\n* All ethnic backgrounds\n* Normal lifetime BMI according to CDC\n\nExclusion Criteria:\n\nWeight Recovered Anorexia Nervosa (AN)\n\n* Current pregnancy or nursing (will have to agree to contraceptive measures if sexually active)\n* Lifetime history of bipolar I disorder or psychosis\n* Current substance abuse or dependence in the past 3 months\n* Psychotic illness\u002Fother organic brain syndromes, dementia, somatization disorders or conversion disorders\n* History of significant head trauma\n* Indication of intellectual disability or autism spectrum disorder\n\nHealthy Control Group\n\n* No lifetime psychiatric illness and in particular no eating disorder history\n* Not be taking medication, and will not have a first degree relative with an eating disorder.\n\nNo subject in either group will have or be\n\n* mental retardation or pervasive developmental disorder\n* organic brain syndrome\n* dementia\n* psychotic disorder\n* bipolar disorder\n* somatic symptom\n* conversion disorder\n* current alcohol or substance use disorder\n* indication of major medical illness including a history of seizure disorder\n* pregnant or nursing at the time of the study\n* a history of traumatic brain injury.\n* diabetes mellitus or other metabolic disorders that could worsen on a ketogenic diet\n* intracranial or any other metal object within or near the head that cannot be safely removed, excluding the mouth\n* implanted neurostimulators, intracardiac lines, or heart disease",{"count":501,"type":23},90,[26],"This is a longitudinal study with an open design in weight recovered anorexia nervosa (wrAN) individuals. Healthy controls (HC) will also be assessed. Study participants will be carefully assessed and will have 18F-fluorodeoxyglucose (\\[18F\\]FDG) positron emission tomography (PET) scans for assessment of regional brain glucose uptake. The wrAN group will be compared to healthy controls. Participants in the wrAN group will then complete 14 weeks of therapeutic ketogenic diet (TKD). At the end of the TKD study, participants will have assessments and a second \\[18F\\]FDG and TMS\u002FEEG scan. Study participants will be followed over six months after the intervention. This follow-up procedure will help determine whether symptom improvement will be stable or worsen in individuals who choose to continue or discontinue the TKD intervention. This will be a naturalistic follow-up.",[30],{"date":487,"type":46},{"date":507,"type":46},"2024-10-02",{"date":509,"type":23},"2030-01",{"name":431,"class":52},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":244,"sex":18,"minAge":359,"maxAge":519,"enrollmentInfo":520,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":522,"conditions":523,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":537},"100629733","cognitive-evaluation-of-patients-with-eating-disorders-100629733","NCT07478510","Cognitive Evaluation of Patients With Eating Disorders","Neuro-cognitive Profiles of Patients With Nutritional and Eating Disorders","DNA_ARFID","Inclusion Criteria:\n\n* Diagnosis of a Feeding and Eating Disorder (ARFID, anorexia nervosa, or bulimia nervosa);\n* Patients of both sexes;\n* Age between 14 and 65 years;\n* Confirmed diagnosis of a Feeding and Eating Disorder;\n* Body Mass Index (BMI) \\\u003C 25;\n* Signed informed consent form for participation in the study.\n\nExclusion Criteria:\n\n* Diagnosis of Bipolar Disorder according to DSM-5-TR criteria;\n* Diagnosis of a Schizophrenia Spectrum Disorder according to DSM-5-TR criteria;\n* Intellectual disability according to DSM-5-TR criteria;\n* Presence of brain tumors;\n* History of seizure events;\n* Presence of other moderate to severe neurological disorders;\n* Lack of the patient's consent to voluntary participation in the study;\n* Lack of parental or legal guardian consent for participation of a minor in the study.","65 Years",{"count":521,"type":23},84,"The goal of this cross - sectional observational study is to improve understanding of the psychological and cognitive characteristics of Feeding and Eating Disorders (FEDs), a group of conditions that represent a growing public health concern due to their significant impact on physical health, emotional well-being, and everyday functioning. Within this broader diagnostic category, particular attention is given to Avoidant\u002FRestrictive Food Intake Disorder (ARFID), a diagnosis introduced in the DSM-5 and still relatively underexplored compared to other feeding and eating disorders.\n\nDespite its clinical relevance, ARFID remains less well understood in terms of its underlying cognitive and psychological mechanisms. Individuals with ARFID often experience severe food avoidance or restriction that is not driven by weight or shape concerns, but rather by sensory sensitivities, fear of negative consequences of eating, or a lack of interest in food. For this reason, investigating ARFID can offer important insights into the diversity of mechanisms involved in feeding and eating disorders as a whole.\n\nThe study has two main objectives. The first objective is to examine the cognitive profile of individuals with ARFID, with a specific focus on autistic traits and cognitive flexibility, as previous research suggests potential overlaps between ARFID and neurodevelopmental conditions such as Autism Spectrum Disorders. Cognitive flexibility refers to the ability to adapt thoughts and behaviors in response to changing situations, and reduced flexibility may contribute to rigid eating patterns and food avoidance.\n\nThe second objective is to explore the role of body representation (how individuals perceive and mentally represent their own body) and inhibitory control (the ability to regulate or suppress automatic responses) in shaping the cognitive and behavioral features of ARFID and other feeding and eating disorders. These processes may help distinguish ARFID from other diagnoses and clarify shared and disorder-specific mechanisms across the FED spectrum.\n\nThe study involves adult participants of all genders, including individuals diagnosed with ARFID, anorexia nervosa, and bulimia nervosa, as well as healthy control participants without a history of feeding or eating disorders. This design allows meaningful comparisons between different diagnostic groups and with the general population.\n\nThe main questions the study aims to answer are:\n\nDo individuals with ARFID show a distinct cognitive profile, particularly in terms of autistic traits and cognitive flexibility, compared to individuals with other feeding and eating disorders and healthy controls?\n\nHow do body representation and inhibitory control contribute to differences in eating-related behaviors across feeding and eating disorders?\n\nAre there differences in brain activity associated with implicit, automatic attitudes toward food in individuals with feeding and eating disorders compared to healthy individuals?\n\nWhere comparison groups are included, researchers will compare participants with ARFID, anorexia nervosa, bulimia nervosa, and healthy controls to examine differences in cognitive functioning, psychological characteristics, and neural responses related to food processing.\n\nParticipants will be asked to take part in a series of non-invasive and well-established research activities, designed to be accessible and safe. These include:\n\nCompleting self-report questionnaires assessing autistic traits, body image perception, and general psychological well-being;\n\nPerforming computer-based tasks that assess cognitive flexibility and decision-making;\n\nCompleting behavioral tasks designed to measure inhibitory control and automatic associations with food-related stimuli;",[524,30,31,525,526,527],"ARFID","Cognitive Flexibility","Implicit Association Test","Executive Functions","2026-04-15",{"date":530,"type":46},"2026-04-16",{"date":532,"type":46},"2024-11-26",{"date":534,"type":23},"2028-03-31",{"name":536,"class":52},"Istituti Clinici Scientifici Maugeri SpA",3,{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":545,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":53},"100611209","developing-an-artificial-intelligence-ai-chatbot-for-adolescents-and-young-adults-with-eating-disorders-100611209","NCT07237607","Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders","Developing an Artificial Intelligence (AI)-Powered Exposure Therapy Chatbot for Adolescents and Young Adults With Eating Disorders","Inclusion Criteria:\n\n* Age is between or equal to 12-26 years\n* Admitted to the Penn State Health Eating Disorder Partial Hospital Program (PHP) or Intensive Outpatient Program (IOP)\n* Have a personal smartphone\n* Have a diagnosis of anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), or other specified feeding or eating disorder (OSFED)\n* Be English speaking\n\nExclusion Criteria:\n\n* Diagnosis of avoidant\u002Frestrictive food intake disorder (ARFID)\n* Have acute suicidality\n* Diagnosis of an intellectual disability","26 Years",{"count":160,"type":23},[26],"The goal of this study is to develop and refine an artificial intelligence (AI)-powered Exposure Therapy for Eating Disorders chatbot web-app that effectively engages adolescents and young adults and decreases anxiety about weight gain. Participants will use the web-app as a supplemental therapeutic tool during their first six weeks of treatment in a Partial Hospitalization Program. Participants will complete assessments every two weeks, including: (1) semi-structured interviews about their experience with the chatbot web-app; (2) implementation outcome measures (e.g., feasibility, usability, acceptability); and (3) anxiety about weight gain.",[29,30,31,550],"Binge-Eating Disorder","2026-04-14",{"date":528,"type":46},{"date":554,"type":46},"2026-03-23",{"date":556,"type":23},"2027-06-30",{"name":558,"class":52},"Milton S. Hershey Medical Center",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":18,"minAge":359,"maxAge":158,"enrollmentInfo":566,"targetDuration":4,"studyType":24,"phases":568,"briefSummary":569,"conditions":570,"keywords":571,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":580,"locationsCount":53},"100607407","adapting-exposure-for-adolescent-an-100607407","NCT07188155","Adapting Exposure for Adolescent AN","Adapting Exposure Therapy to Target Anxiety About Weight Gain in Adolescents With Anorexia Nervosa","Inclusion Criteria:\n\n* Has a diagnosis of anorexia nervosa (AN)\n* English speaking\n* Mentally stable for an outpatient level of care\n* Living with at least one parent\u002Fcaregiver\n* Less than or equal to 90% of expected body weight\n\nExclusion Criteria:\n\n* Younger than 14 years old or older than 17 years old\n* Has a current psychotherapist and not open to pausing treatment for the duration of the study\n* Has a diagnosis of bulimia nervosa or binge-eating disorder\n* Acutely suicidal\n* Pregnant\n* Meets DSM-5 criteria for a psychotic disorder and\u002For has an intellectual disability\n* Non-English speaking",{"count":567,"type":23},16,[26],"This pilot study is evaluating Exposure Therapy (Exp-AN) as a virtual treatment for adolescents (ages 14 - 17 years) with anorexia nervosa (AN) recruited from eating disorder clinic waitlists and clinician referrals at the Penn State Milton S. Hershey Medical Center and the University of California, San Francisco (UCSF) (8 participants per site). Adolescents who agree to take part in this study will receive 20 free virtual 40-60 minute weekly Exp-AN sessions at an outpatient level of care. Exp-AN for adolescents will combine individual virtual session time (35-50 min) with parent involvement (10-25 min). Parents will serve as \"collaborators,\" supporting skill development, exposure completion, and treatment goal achievement. Exp-AN sessions will focus on helping participants overcome anxiety about weight gain by encouraging them to do challenging things that increase anxiety in the short term but help them better tolerate anxiety over the long term. Participants will be asked to complete a clinical interview, questionnaires, and labs and vitals testing before they begin the study. Adolescents will also complete questionnaires and participate in 15-min semi-structured interviews, while parents\u002Fcaregivers will complete separate parallel interviews, at: mid-treatment, end-of-treatment, and 3-month follow-up. To ensure that all participants are receiving the same type of therapy, they will not be able to have any concurrent psychotherapy while receiving this treatment (other forms of care including dieticians, nutritionists, and psychiatrists are allowed).\n\nExp-AN is designed to target anxiety about weight gain. Exp-AN includes education about the effects of undereating; the importance of overcoming anxiety about weight gain; in-session weight exposures (e.g., stepping on a scale while reading a script describing fears about weight gain); creating a meal plan to help improve eating; reviewing eating behaviors over the past week; conducting in-session and between-session exposures that help participants face fears related to weight gain; and relapse prevention.",[30],[169,572,573],"exposure therapy","adolescents","2026-04-07",{"date":576,"type":46},"2026-04-08",{"date":578,"type":46},"2026-02-20",{"date":556,"type":23},{"name":558,"class":52},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":244,"sex":106,"minAge":19,"maxAge":588,"enrollmentInfo":589,"targetDuration":4,"studyType":24,"phases":591,"briefSummary":592,"conditions":593,"keywords":594,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":351},"100293499","study-of-food-aversion-in-patients-with-anorexia-nervosa-100293499","NCT03100656","Study of Food Aversion in Patients With Anorexia Nervosa","Solving EPHX2 and Polyunsaturated Fatty Acid Interactions in Anorexia Nervosa","Inclusion Criteria:\n\n* Ill AN subjects will meet current Diagnostic and Statistical Manual of Mental Disorders (DSM V) diagnosis of AN, body mass index (BMI) between 11 kg\u002Fm² and 17.5 kg\u002Fm², or BMI \\> 17.5 kg\u002Fm² with active eating disorder symptoms.\n* Recovered AN must meet the following criteria at time of study entry: 1) Current or past DSM V diagnosis of AN; 2) BMI between 18.5 kg\u002Fm2 and 30 kg\u002Fm2; 3) Having maintained a BMI of \\>18.5 for at least one year.\n* Control must be healthy adolescent or woman negative on our screen for AN, other Axis I psychiatric illnesses, and having maintained a BMI of between 18.5-30 kg\u002Fm² since the age of 18.\n\nExclusion Criteria:\n\n* Exclusion criteria for AN and control subjects include: Organic brain syndrome, schizophrenia and schizoaffective disorder, untreated thyroid disease, renal disease, hepatic disease, and the regular use of fish-oil containing supplements within the last three months of the study. All pregnant and lactating individuals will be excluded.","55 Years",{"count":590,"type":23},300,[26],"This study uses a meal-challenge protocol to assess if patients with anorexia nervosa show a differential metabolism in response to food in comparison to healthy controls. This study determines how heritable and biochemical factors influence food metabolism in anorexia nervosa in order to develop more effective treatment strategies.",[30],[595,596,597,598,599],"psychopathology","treatment","epoxide hydrolases","polyunsaturated fatty acids","eicosanoids","2026-03-28",{"date":602,"type":46},"2026-03-31",{"date":604,"type":46},"2016-11-10",{"date":606,"type":23},"2027-12-31",{"name":431,"class":52},{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":106,"minAge":61,"maxAge":19,"enrollmentInfo":616,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":617,"conditions":618,"keywords":619,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":628,"locationsCount":53},"100577626","body-composition-in-adolescents-with-anorexia-nervosa-100577626","NCT06800742","Body Composition in Adolescents With Anorexia Nervosa","Body Composition, Resting Energy Expenditure and Physical Activity in Adolescents With Anorexia Nervosa","COCOMETANNER","Adolescents with Anorexia Nervosa:\n\nInclusion Criteria:\n\n* Female sex\n* Age range: 12-18 years\n* Anorexia nervosa\n* Hospitalized at the Division of Auxologia, San Giuseppe Hospital, Istituto Auxologico Italiano, IRCCS, Piancavallo, Italy\n\nExclusion Criteria:\n\n* Absence of signed informed consent\n\nAdolescents with normal weight:\n\nInclusion Criteria:\n\n* Female sex\n* Age range: 12-18 years\n* Normal weight\n\nExclusion Criteria:\n\n* Absence of signed informed consent",{"count":137,"type":23},"Body Mass Index (BMI) is currently the most widely recommended parameter for identifying underweight subjects. Among eating disorder diseases, anorexia nervosa (AN) is the one with the highest mortality rate and with relapses between 12 and 27%. To date, recovery programs allow approximately 40% of subjects to achieve recovery, 30% demonstrate improvements, and 20% remain chronically affected. These data demonstrate the importance of continuously monitoring changes in weight and body composition of these subjects. Bioelectrical impedance (BIA) is widely used to determine body composition in AN. BIA provides various parameters, such as lean mass (LM), fat mass (FM), total body water (TBW), and phase angle (PhA). Among these parameters, in addition to LM and FM, PhA has also been used to characterize underweight subjects with AN. In addition to the observed relationship between PhA and body composition in individuals with AN, PhA has also been related to the basal metabolic rate (BMR). BMR undergoes changes mainly due to loss of muscle mass and a significant reduction in BMR has been observed in AN subjects. Finally, physical activity represents a significant determinant of body composition and can help regulate BMR.\n\nTherefore, monitoring changes in body composition (LM, FM, and PhA) and indirect indices (lean mass index and fat mass index) using BIA, together with monitoring changes in BMR and physical activity level, could provide important support for the continuous control and definition of the clinical stage of the disease in patients with AN.\n\nThe aim of this study is to determine body composition, basal metabolic rate, and level of physical activity in Anorexia Nervosa and normal weight subjects to identify the most consistent parameters to define the clinical stage of the disease in subjects with AN.",[30],[167,620,621],"Resting energy expenditure","Hyperactivity","2026-03-25",{"date":624,"type":46},"2026-03-30",{"date":626,"type":46},"2024-07-12",{"date":348,"type":23},{"name":629,"class":52},"Istituto Auxologico Italiano"]